U.S. Sen. Sherrod Brown and a top AARP official say that a shorter exclusivity period for brand-name biologic drugs would help promote innovation and allow for affordable, generic versions to be produced.

Biologic drugs are produced from living organisms or its products and are generally used to prevent, diagnose or treat certain health conditions, such as cancer, multiple sclerosis and lupus.

They are typically more expensive and can cost up to 22 times more to purchase than regular prescription drugs, said Brown, D-Ohio.

To read the rest of this article, please click the source link above.